Phase I trial of the Pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3160-3169

  Brown, Jennifer R ^a   Davids, Matthew S ^a   Rodon, Jordi ^b   Abrisqueta, Pau ^b   Kasar, Siddha N ^a   Lager, Joanne ^c   Jiang, Jason ^d   Egile, Coumaran ^d   Awan, Farrukh T ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Sanofi Oncology   (United States)

^d SANOFI   (France)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PILARALISIB; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; ADVERSE DRUG REACTION; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BACKACHE; BLOOD LEVEL; CANCER PATIENT; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LYMPH NODE; LYMPHOCYTE MIGRATION; LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOXALINES; SULFONAMIDES;

EID: 84942290452     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3262     Document Type: Article

References (55)

1. Chao MP Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer Manag Res 2013; 5: 251-69.
2. Palma M, Kokhaei P, Lundin J, Choudhury A, Mellstedt H, Osterborg A. The biology and treatment of chronic lymphocytic leukemia. Ann Oncol 2006; 17 Suppl 10: x144-54.
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-15.
4. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-43.
5. Brown JR, Porter DL, O'Brien SM. Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol Educ Book 2014; e317-25.
6. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-44.
7. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-56.
8. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27: 5486-96.
9. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 2013; 8: e83830.
10. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009; 15: 5724-32.
11. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012; 442: 465-81.
12. ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B-cell receptor. Clin Cancer Res 2014; 20: 548-56.
13. Hasselblom S, Hansson U, Olsson M, Toren L, Bergstrom A, Nilsson-Ehle H, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010; 149: 560-8.
14. Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol 2013; 92: 1351-8.
15. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
16. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-506.
17. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 3791-802.
18. Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013; 110: 12420-5.
19. Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013; 121: 2274-84.
20. Abubaker J, Bavi PP, Al Harbi S, Siraj AK, Al Dayel F, Uddin S, et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2368-70.
21. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013; 110: 1398-403.
22. Marincevic M, Tobin G, Rosenquist R. Infrequent occurrence of PIK3CA mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 829-30.
23. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-5.
24. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002; 297: 1031-4.
25. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-88.
26. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-12.
27. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-4.
28. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
29. Gopal AK, Kahl BS, DeVos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-18.
30. Gilead Sciences Inc. ZYDELIG® (idelalisib) tablets, Prescribing Information, FDA. 2014; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206545lbl.pdf
31. Brown JR, Hamadani M, Arnason J, Karlin L, Hayslip J, Wagner-Johnston N, et al. SAR245409 monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study. Blood 2013; 122: 86.
32. Burris HA III, Patel MR, Brander DM, O'Connor OA, Deng C, Fenske TS, et al. TGR-1202, a novel once daily PI3Kd inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with chronic lymphocytic leukemia and B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2014; 124: abstr 1984.
33. Dreyling M, Morschhauser F, Bron D, Bouabdallah K, Vitolo U, Linton K, et al. Preliminary results of a Phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Blood (ASH Annual Meeting Abstracts) 2013; 122: abstr 87.
34. Flinn I, Patel M, Kahl BS, Horwitz SM, Foss FM, Oki Y, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta, gamma, in patients with chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2013; 122: abstr 677.
35. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 2013; 133: 247-52.
36. Sidhu SS, Egile C, Malfilatre M, Lefranc C, Ruffin Y, Ma J, et al. Antitumor activity of Pimasertib in combination with SAR245409 or SAR245408 in human primary colorectal cancer xenograft models bearing PI3K/KRAS and KRAS Mutations. AACR 2013; 73: abstr 4638.
37. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014; 20: 233-45.
38. Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, et al. The selective PI3K inhibitor XL147 (SAR245408) inhibits tumor growth and survival and potentiates the activity of chemo therapeutic agents in preclinical tumor models. Mol Cancer Ther 2015; 14: 931-40.
39. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. 2006. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf
40. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-9.
41. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-56.
42. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
43. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30: 2820-2.
44. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-7.
45. O'Brien SM, Lamanna N, Kipps IF, Flinn I, Zelenetz AD, Burger JA, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kd) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) >/= 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 2013; 31 (suppl): abstr 7005.
46. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-9.
47. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740-6.
48. Arkenau H-T, Fields Jones S, Kurkjian C, Infante JR, Pant S, Burris HA, et al. The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. J Clin Oncol 2012; 30: abstr 3097.
49. Bendell C, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-90.
50. Benson DM, Kahl BS, Furman RR, Brown JR, Wagner-Johnston ND, Coutre SE, et al. Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kd, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). J Clin Oncol 2013; 31 (suppl): abstr 8526.
51. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 4173-82.
52. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 2012; 23: 2399-408.
53. Patnaik A, Ramanathan RK, Appleman LJ, Tolcher AW, Mountz AW, Beerham M, et al. Phase I study of intravenous PI3K inhibitor Bay 80-6946: preliminary activity in patients with relapsed non-Hodgkin lymphoma (NHL) treated in an MTD expansion cohort. ASH Annual Meeting 2012: abstr 3704.
54. Spurgeon SEF, Wagner-Johnston ND, Furman RR, Flinn I, Coutre SE, Brown JR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110d (PI3Kd), in patients with relapsed or refractory mantle cell lymphoma (MCL). J Clin Oncol 2013; 31 (suppl): abstr 8519.
55. Wagner AJ, Bendell JC, Dolly S, Morgan JA, Ware JA, Fredrickson J, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 2011; 29: abstr 3020.